Core Viewpoint - Azitra, Inc. is set to present at the Biotech Showcase 2025, highlighting its innovative therapies for precision dermatology and engaging with investors and potential partners [1][2]. Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for precision dermatology, with its lead product ATR-12 targeting Netherton syndrome, a rare skin disease [4]. - ATR-12 is currently in a Phase 1b clinical trial for adult patients, while ATR-04 is being developed for EGFR inhibitor associated rash and has received Fast Track designation from the FDA [4]. - The company utilizes a proprietary platform of engineered proteins and a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning technologies [4]. Event Details - The Biotech Showcase 2025 will take place from January 13-15, 2025, in San Francisco, with Azitra's COO Travis Whitfill presenting on January 13 at 3:00 p.m. PT [2][3]. - Azitra's management team will conduct one-on-one meetings with registered investors to discuss the company's business strategy, recent achievements, and future milestones [2].

Financial Performance - The company reported $0 service revenue for Q3 2024, down from $310,700 in Q3 2023[2] - Research and Development (R&D) expenses increased to $1.0 million in Q3 2024 from $0.5 million in Q3 2023, a 100% increase[3] - General and Administrative (G&A) expenses rose to $1.9 million in Q3 2024 compared to $1.8 million in Q3 2023[3] - The net loss for Q3 2024 was $1.0 million, an improvement from a net loss of $1.9 million in Q3 2023[3] - As of September 30, 2024, cash and cash equivalents stood at $7.3 million, up from $1.8 million at the end of 2023[4] Corporate Developments - Azitra completed a follow-on offering generating $10 million in gross proceeds[1] - Azitra strengthened its intellectual property portfolio with newly granted and allowed patents during the quarter[1] Clinical Trials and Regulatory Updates - The company anticipates initial safety data from the Phase 1b trial for Netherton syndrome patients in Q1 2025[2] - Azitra plans to dose the first patient with ATR-04 for EGFRi rash in a Phase 1/2 trial in Q1 2025[2] - The company has received Fast Track designation from the FDA for ATR-04, which targets EGFRi associated rash affecting approximately 150,000 patients in the U.S.[6]

Core Insights - Azitra, Inc. reported significant progress in Q3 2024, including the dosing of the first patient with ATR-12 for Netherton syndrome and the completion of a $10 million follow-on offering [2][3] - The company received FDA Fast Track designation for ATR-04, which is aimed at treating skin rash associated with EGFR inhibitors [2][3] - Azitra's financial results showed a net loss of $1.0 million for the quarter, a decrease from a loss of $1.9 million in the same period last year [3][9] Business Highlights - Completed a follow-on offering generating $10 million in gross proceeds [2] - Dosed the first patient with ATR-12 in the ongoing Netherton syndrome trial [2] - Submitted and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitors [2] - Presented positive preclinical data for ATR-04 at the EADV Congress [2] - Strengthened the intellectual property portfolio with newly granted patents [2] Pipeline and Anticipated Milestones - Q1 2025: Initial safety data from Netherton syndrome patients in Phase 1b trial [3] - Q1 2025: First patient dosed with ATR-04 for EGFRi rash in Phase 1/2 trial [3] - YE 2025: Topline data from the Phase 1b trial with ATR-12 expected [3] Financial Results - Service revenue for Q3 2024 was $0, down from $310,700 in Q3 2023 [3][9] - R&D expenses increased to $1.0 million from $0.5 million year-over-year [3][9] - G&A expenses slightly increased to $1.9 million from $1.8 million year-over-year [3][9] - Cash and cash equivalents as of September 30, 2024, were $7.3 million [3][9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4478536 (State or other juri ...

Exhibit 99.1 Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates BRANFORD, Conn. — Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights ● Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4478536 (State or other jurisdict ...

Azitra (NYSEMKT:AZTR) stock is falling hard on Wednesday morning after the biopharmaceutical company’s shares underwent a massive rally yesterday.Azitra stock is down 75.2% as of Wednesday morning. That comes with some 6.3 million shares of the stock traded. For the record, the company’s daily average trading volume is about 1.3 million shares.Yesterday’s trading saw the tock close out normal hours up 206.8%. That came with more than 75 million shares of AZTR stock changing hands. Unfortunately for investor ...

Azitra (NYSEMKT:AZTR) stock is taking off on Tuesday after the early-stage biopharmaceutical company provided investors with updates on its patents.This covers the company’s filaggrin-secreting strain of Staphylococcus epidermidis. A patent was issued to it on July 16 U.S. Patent and Trademark Office (USPTO). That includes future potential pipeline candidates for indications including atopic dermatitis.On top of this, Azitra announced three newly allowed patents in the U.S., Canada, and China. The U.S. pate ...

Clinical Trials and Development Progress - ATR-12 Phase 1b trial advanced with clinical sites activated and initial Netherton syndrome patients identified for dosing, with primary endpoints focusing on safety and tolerability[2] - ATR-04 pre-IND meeting with FDA successfully completed, with IND submission planned for mid-2024 and Phase 1b trial initiation targeted for late 2024[2][3] - ATR-12 preclinical data presented at ASGCT shows superior LEKTI delivery and significant reduction of IL-36g, a pro-inflammatory cytokine implicated in Netherton syndrome[2][3] Financial and Funding Updates - Follow-on public offering completed in February 2024, raising $5.0 million in gross proceeds to support clinical programs[4] - Q1 2024 R&D expenses increased to $1.5 million compared to $0.8 million in Q1 2023[6] - Q1 2024 net loss was $2.9 million, compared to $2.5 million in Q1 2023[6] - Cash and cash equivalents as of March 31, 2024, totaled $3.0 million[6] Market Potential and Intellectual Property - ATR-12 estimated peak sales opportunity is ~$250 million, targeting a global prevalence of 20,000+ Netherton syndrome patients[4] - ATR-04 estimated peak sales opportunity exceeds $1 billion, targeting a U.S. prevalence of ~150,000 EGFRi-associated rash patients[5] - U.S. patent issued for treating skin diseases, including ichthyosis vulgaris, affecting approximately 1.3 million Americans[4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | --- | |----------------- ...